{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:45:31Z","timestamp":1793047531631,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Research: Neuroimaging"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.pscychresns.2010.05.002","type":"journal-article","created":{"date-parts":[[2010,7,11]],"date-time":"2010-07-11T23:36:10Z","timestamp":1278891370000},"page":"151-156","source":"Crossref","is-referenced-by-count":67,"title":["Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia:"],"prefix":"10.1016","volume":"183","author":[{"given":"Onno L.","family":"de Klerk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoon T.M.","family":"Willemsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fokko J.","family":"Bosker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Harry","family":"Hendrikse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan A.","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy A.","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pscychresns.2010.05.002_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00259-007-0556-5","article-title":"Peripheral metabolism of (R)-[(11)C]verapamil in epilepsy patients","volume":"35","author":"Abrahim","year":"2008","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jpsychires.2007.10.007","article-title":"Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting","volume":"42","author":"Alenius","year":"2008","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","article-title":"Biochemical, cellular, and pharmacological aspects of the multidrug transporter","volume":"39","author":"Ambudkar","year":"1999","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.mp.4000650","article-title":"Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment","volume":"5","author":"Arolt","year":"2000","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00702-008-0030-y","article-title":"Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA","volume":"115","author":"Bartels","year":"2008","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/153537020523000206","article-title":"Modulation of p-glycoprotein transport function at the blood-brain barrier","volume":"230","author":"Bauer","year":"2005","journal-title":"Experimental Biology and Medicine (Maywood.)"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/mol.106.029512","article-title":"Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier","volume":"71","author":"Bauer","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-5-78","article-title":"Cancer cell adaptation to chemotherapy","volume":"5","author":"Di","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00007691-200404000-00017","article-title":"Clinical aspects of the MDR1 (ABCB1) gene polymorphism","volume":"26","author":"Eichelbaum","year":"2004","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib11","first-page":"49","article-title":"Cytokines in degenerative brain diseases: lessons from transgenic animals","volume":"265","author":"Eisel","year":"2002","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds\u2014implications for pharmacokinetics of selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2174\/1381612043384736","article-title":"PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS","volume":"10","author":"Elsinga","year":"2004","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib14","first-page":"359","article-title":"Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality","volume":"7","author":"Fernandez","year":"2004","journal-title":"Journal of Pharmacy & Pharmaceutical Sciences"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib15","doi-asserted-by":"crossref","first-page":"RC216","DOI":"10.1523\/JNEUROSCI.22-07-j0001.2002","article-title":"Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2","volume":"22","author":"Fontaine","year":"2002","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.npp.1300446","article-title":"Prenatal infection and risk for schizophrenia: IL-I\u00df, IL-6 and TNF\u03b1 inhibit cortical neuron dendrite development","volume":"29","author":"Gilmore","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2350-6-7","article-title":"Theories of schizophrenia: a genetic-inflammatory-vascular synthesis","volume":"6","author":"Hanson","year":"2005","journal-title":"BMC Medical Genetics"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pscychresns.2006.02.006","article-title":"Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naive schizophreniform psychosis","volume":"148","author":"Harrison","year":"2006","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/mol.105.017954","article-title":"Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide","volume":"69","author":"Hartz","year":"2006","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib20","first-page":"2411","article-title":"A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier","volume":"59","author":"Hendrikse","year":"1999","journal-title":"Cancer Research"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib21","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1176\/appi.ajp.162.12.2233","article-title":"Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies","volume":"162","author":"Honea","year":"2005","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/00004647-200210000-00015","article-title":"Strategies to improve neuroreceptor parameter estimation by linear regression analysis","volume":"22","author":"Ichise","year":"2002","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1358\/mf.2002.24.8.705071","article-title":"P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance","volume":"24","author":"Johnson","year":"2002","journal-title":"Methods & Findings in Experimental & Clinical Pharmacology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib24","doi-asserted-by":"crossref","unstructured":"Kastelic, M., Koprivsek, J., Plesnicar, B.K., Serretti, A., Mandelli, L., Locatelli, I., Grabnar, I., Dolzan, V., 2010. MDR1 gene polymorphisms and response to acute risperidone treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 34 (2), 387--392.","DOI":"10.1016\/j.pnpbp.2010.01.005"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbr.2007.11.009","article-title":"Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice","volume":"188","author":"Kirschbaum","year":"2008","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.20369","article-title":"Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo","volume":"57","author":"Kortekaas","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.psychres.2007.06.006","article-title":"The influence of 5-HT2C and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients","volume":"160","author":"Kuzman","year":"2008","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib29","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.ftd.0000246761.82377.a6","article-title":"The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia","volume":"28","author":"Lin","year":"2006","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0969-8051(00)00137-2","article-title":"Graphical analysis of PET data applied to reversible and irreversible tracers","volume":"27","author":"Logan","year":"2000","journal-title":"Nuclear Medicine and Biology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","article-title":"Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine","volume":"62","author":"Lown","year":"1997","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.jcbfm.9600349","article-title":"Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET","volume":"27","author":"Lubberink","year":"2007","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1592\/phco.21.9.778.34558","article-title":"Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation","volume":"21","author":"Matheny","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib34","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1176\/ajp.156.4.634","article-title":"Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia","volume":"156","author":"M\u00fcller","year":"1999","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib35","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/schbul\/sbi034","article-title":"Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia","volume":"31","author":"Pantelis","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-3565(24)39245-6","article-title":"Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein","volume":"293","author":"Pauli-Magnus","year":"2000","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.14712\/fb2006052060184","article-title":"Polymorphisms of the MDR1 gene in the Czech population","volume":"52","author":"Pechandova","year":"2006","journal-title":"Folia Biologica (Praha)"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib38","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/17425255.4.10.1245","article-title":"A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain","volume":"4","author":"Roberts","year":"2008","journal-title":"Expert Opinion on Drug Metabolism & Toxicologyl"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/brbi.2001.0648","article-title":"Review of immunological and immunopathological findings in schizophrenia","volume":"15","author":"Rothermundt","year":"2001","journal-title":"Brain, Behavior, and Immunity"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib40","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026043387692","article-title":"Pharmacogenetics of drug transporters and its impact on the pharmacotherapy","volume":"4","author":"Sakaeda","year":"2004","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib41","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clpt.2005.01.022","article-title":"Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography","volume":"77","author":"Sasongko","year":"2005","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib43","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/oxfordjournals.schbul.a006881","article-title":"Regionally diverse cortical pathology in schizophrenia: clues to the etiology of the disease","volume":"27","author":"Selemon","year":"2001","journal-title":"Schizophrenia Bulletin"},{"issue":"Suppl 20","key":"10.1016\/j.pscychresns.2010.05.002_bib45","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12017-008-8041-2","article-title":"Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia","volume":"10","author":"Shinkai","year":"2008","journal-title":"Neuromolecular Medicine"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2990.2008.01005.x","article-title":"Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases","volume":"35","author":"Stolp","year":"2009","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib48","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1097\/00001756-200212200-00042","article-title":"Evaluation of the role of P-glycoprotein in inflammation induced blood-brain barrier damage","volume":"13","author":"Tan","year":"2002","journal-title":"NeuroReport"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neulet.2004.09.046","article-title":"Analysis of MDR1 haplotypes in Parkinson's disease in a white population","volume":"372","author":"Tan","year":"2004","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jpsychires.2005.10.005","article-title":"Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls","volume":"41","author":"Uhr","year":"2007","journal-title":"Journal of Psychiatric Research"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib51","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein","volume":"7","author":"Wang","year":"2004","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib54","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1055\/s-2005-916184","article-title":"Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy","volume":"38","author":"Weber","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0969-8043(02)00143-4","article-title":"An improved method for the preparation of [11C]verapamil","volume":"57","author":"Wegman","year":"2002","journal-title":"Applied Radiation and Isotopes"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1389200043489108","article-title":"The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function","volume":"5","author":"Woodahl","year":"2004","journal-title":"Current Drug Metabolism"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib57","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2217\/14622416.7.7.987","article-title":"Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients","volume":"7","author":"Xing","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","article-title":"Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Britisch Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib59","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pnpbp.2005.06.019","article-title":"Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study","volume":"30","author":"Yasui-Furukori","year":"2006","journal-title":"Progress in Neuropsychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib60","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.pnpbp.2007.04.021","article-title":"Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients","volume":"31","author":"Yasui-Furukori","year":"2007","journal-title":"Progress in Neuropsychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pscychresns.2010.05.002_bib61","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.npp.1301181","article-title":"Risperidone and paliperidone inhibit p-glycoprotein activity in vitro","volume":"32","author":"Zhu","year":"2007","journal-title":"Neuropsychopharmacology"}],"container-title":["Psychiatry Research: Neuroimaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925492710001587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925492710001587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T20:36:07Z","timestamp":1740256567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925492710001587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0925492710001587"],"URL":"https:\/\/doi.org\/10.1016\/j.pscychresns.2010.05.002","relation":{},"ISSN":["0925-4927"],"issn-type":[{"value":"0925-4927","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}